Mitochondrial function in thoracic aortic aneurysms

Emma Yu, Kirsty Foote, Martin Bennett

Division of Cardiovascular Medicine
University of Cambridge
Box 110 ACCI
Addenbrooke’s Hospital
Cambridge
CB22 0QQ, UK

For correspondence:
Telephone (44)1223 331504
Fax (44)1223 331505
Email: epky2@cam.ac.uk
mrb@mole.bio.cam.ac.uk

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Mitochondria contain multiple copies of mitochondrial DNA (mtDNA) that encode ribosomal and transfer RNAs and many essential proteins required for oxidative phosphorylation. Mitochondria are essential for generation of ATP, but also generate reactive oxygen species (ROS) as a by-product of the electron transport chain. Oxidative damage to mitochondrial DNA induces respiratory chain dysfunction, resulting in reduced ATP synthesis and further increased ROS generation. The reduced mitochondrial respiration may be accompanied by increased glycolysis and increased lactate production, and these changes can be detected by reduced oxygen consumption and increased extracellular pH of tissues or cultured cells. Mitochondrial dysfunction leading to reduced mitochondrial respiration has been implicated in both normal vascular ageing and a variety of cardiovascular diseases, including atherosclerosis, heart failure, and aneurysm formation. For example, reduced mitochondrial DNA (mtDNA) copy number, mitochondrial respiration and expression of specific electron transport chain complexes has been shown in vascular smooth muscle cells (VSMCs) derived from human atherosclerotic plaques1-3. Mitochondriogenesis and mitophagy are also important regulators of mitochondrial health and number. ROS induce VSMC mitophagy, and similarly plaque VSMCs show increased mitophagy compared with normal arterial VSMCs.

Mitochondrial dysfunction has been associated with arterial aneurysm formation, but most studies have analysed abdominal aortic aneurysms (AAA) rather than genetic thoracic aortic aneurysmal aorta syndromes. For example, AAA show differential expression of a number of genes associated with mitochondrial function and oxidative phosphorylation4 and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) gene expression is decreased in human AAA and angiotensin (Ang) II-induced AAA in mice. Similarly, the intima/media layer of AAA vessels showed reduced expression of a number of markers of mitochondrial biogenesis, including PGC1α, ATP synthase and citrate synthase5. Mitochondrial dysfunction is also associated with arterial ageing and medial degeneration in humans and mice, associated with changes in arterial expression of genes that regulate mitochondrial number, while correction of mitochondrial dysfunction can delay arterial ageing6. However, mitochondrial dysfunction has not been associated with thoracic aortic aneurysmal syndromes, and its role in causing rather than a consequence of aneurysm formation is unclear.

Fibulin-4 is a secreted glycoprotein which tethers elastic fibres VSMCs, and patients with mutations in Fibulin-4 develop aortic aneurysms, arterial tortuosity and elastin abnormalities. Fibulin-4R/R mice (which have 4-fold reduced Fibulin 4 levels) develop progressive ascending aneurysm formation and early death around 3m of age, with Transforming growth factor β (TGFβ) signalling a critical regulator of aneurysm formation7. In the current edition of CVR, van der Pluijm et al. used proteomics, genomics and functional experiments to study thoracic aortas of aneurysmal Fibulin-4R/R animals. Fibulin-4R/R mice showed alterations in protein composition affecting predominantly extracellular matrix (ECM) and cytoskeleton proteins, but also mitochondrial proteins and upregulation of TGFβ1. VSMCs from Fibulin-4R/R mice had smaller mitochondria, but similar numbers of mitochondria and increased expression of mitochondrial complexes I-IV. VSMCs derived from these mice also showed lower uncoupled oxygen consumption rates, consistent with reduced mitochondrial respiration, but increased acidification rates, perhaps reflecting increased glycolysis. Aortas from aneurysmal Fibulin-4R/R mouse also displayed increased ROS levels. Interestingly lower oxygen consumption was also found in Tgfbr-1M318R+ mouse VSMCs, a mouse model for Loey-Dietz syndrome (TGFBR2 and SMAD3) patients. Fibulin-4R/R mouse aortas had significantly decreased mRNA expression of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and PGC1β compared to Fibulin-4+/+ aortas, and activity of PGC1α, a key regulator of both mitochondrial function and organismal metabolism, was markedly reduced. Interestingly, TGFβ also reduced PGC1α transcription, while activation of
PGC1α increased both basal and maximum oxygen consumption in Fibulin-4R/R VSMCs and improved cell proliferation.

The authors outline a possible pathway linking Fibulin 4 reduction with mitochondrial dysfunction that include ROS, TGFβ, and PGC1α (Figure 1). Thus, Fibulin deficiency leading to disorganised ECM proteins can result in increased TGFβ1 signalling. ROS may induce mtDNA damage and mitochondrial dysfunction, characterised by reduced mitochondrial respiration, a switch of energy substrate for ATP generation, and further increases in ROS. Mitochondrial biogenesis involves an intricate, complicated network of transcription factors that activate target genes encoding enzymes of fatty acid oxidation, oxidative phosphorylation, and anti-oxidant defences. PGC-1α regulates expression of this network, and directly links external physiological stimuli to the regulation of mitochondrial biogenesis and function. Mitochondrial dysfunction would normally result in compensatory mitogenesis, but increased TGFβ1 signalling due to concomitant abnormalities in either ECM proteins or cytoskeletal filaments result in reduced expression and transcriptional activity of PGC1α, and reduced expression and activation of its targets including PPARα, PPARγ and PPARβ. PPARα and γ have major roles regulating expression of proteins involved in extra and intramitochondrial fatty acid transport and oxidation, while PPARβ regulates antioxidant synthesis, such that reduced expression/activity may increase ROS further.

As always, the current paper raises a number of important questions. First, how does a deficiency in a protein involved in ECM structural integrity lead to altered mitochondrial function and metabolism. Although this might be through structural abnormalities in mitochondria, TGFβ signalling (which has been implicated in a number of human aneurysm syndromes) negatively regulates PGC1α levels and may be the major pathway involved. However, arterial ageing, itself associated with ROS and VSMC loss and cell senescence, is accompanied by reductions in mtDNA copy number, mitochondrial respiration, and expression of PGC1α and a number of other genes regulating mtDNA synthesis. The changes noted in Fibulin-4R/R mice may therefore also be due to loss and/or senescence of VSMCs in the arterial wall, with reduced mitochondrial function and increased ROS. MitDNA synthesis is directly regulated by a number of proteins, including the mitochondrial transcription factor A (TFAM), mitochondrial helicase Twinkle, and PGC1α. It would therefore be important to examine mtDNA copy number and mtDNA damage in both mouse models of thoracic aortic aneurysm syndromes and human patients, and markers of mtDNA synthesis and mitochondrial turnover including fission/fusion and mitophagy. In addition, we currently lack effective treatments to prevent arterial expansion and rupture in thoracic aortic aneurysm syndromes, and the current paper raises the possibility that therapy aimed at increasing PGC1α or potent PPARα and γ agonists might be of benefit. If Fibulin-4R/R mice recapitulate the structural abnormalities, mitochondrial dysfunction and cell signalling defects seen in human patients, then preclinical studies using these agents would be important.
Acknowledgements
This work was supported by British Heart Foundation (BHF) grants PG/14/69/31032 and RG/13/14/30314, the National Institute for Health Research Cambridge Biomedical Research Centre, the BHF Centre for Research Excellence, the Academy of Medical Sciences.
References


Figure 1
Model implicating mitochondrial dysfunction in aortic aneurysm formation
A full description is provided in the text

ECM; extracellular matrix. VSMC; vascular smooth muscle cell. TGFβ; transforming growth factor beta. PGC1α; peroxisome proliferator activated receptor gamma coactivator 1 alpha. OCR; oxygen consumption rate. ECAR; extracellular acidification rate. Tw; Twinkle helicase. ROS; reactive oxygen species. ATP; adenosine triphosphate.